Literature DB >> 7182952

Immunochemical heterogeneity of human plasma apolipoprotein B. II. Expression of apolipoprotein B epitopes on native lipoproteins.

B P Tsao, L K Curtiss, T S Edgington.   

Abstract

Eleven hybridoma antibodies specific for apoprotein B were used to examine the expression of apoprotein B epitopes on native plasma lipoproteins using fluid phase radioimmunoassays. Heterogeneity of apoprotein B in low density lipoprotein (LDL) of density 1.019-1.063 g/ml was indicated by maximum binding of radioiodinated LDL in the presence of excess antibody that ranged from 45 to 100%. Affinity constants for LDL ranged from 0.29-3.0 X 10(9) M-1. Each of the 11 antibodies recognized apoprotein B epitopes that were expressed by very low, intermediate, and low density lipoproteins, VLDL, IDL, and LDL, respectively, since at high concentrations, each could fully displace the binding of radioiodinated LDL. In contrast, these same apoprotein B epitopes were not present on high density lipoproteins. Logit transformation analysis of competitive inhibition titrations demonstrated at least three patterns of epitope expression. The first pattern, identified by five of the antibodies, was characterized by indistinguishable expression of each of the apoprotein B epitopes on VLDL, IDL, and LDL. The second pattern, identified by three antibodies, was characterized by identical expression of the apoprotein B epitopes on VLDL and IDL, but of differing affinities than the related epitope on LDL. Three antibodies identified a third pattern of epitope expression which was was characterized by identical expression on IDL and LDL, but with differing affinities for the antibodies than the same epitopes on VLDL. These observations suggest that the organization of apoprotein B in VLDL, IDL, and LDL is similar, but not identical.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7182952

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B.

Authors:  S G Young; S J Bertics; L K Curtiss; D C Casal; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

2.  Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women.

Authors:  E A Brinton; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins.

Authors:  E S Krul; M J Tikkanen; T G Cole; J M Davie; G Schonfeld
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100.

Authors:  S G Young; S J Bertics; L K Curtiss; B W Dubois; J L Witztum
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

5.  Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals.

Authors:  R Terkeltaub; L K Curtiss; A J Tenner; M H Ginsberg
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

6.  A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins.

Authors:  L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

7.  Human apolipoprotein B: identification of cDNA clones and characterization of mRNA.

Authors:  M Mehrabian; V N Schumaker; G C Fareed; R West; D F Johnson; T Kirchgessner; H C Lin; X B Wang; Y H Ma; E Mendiaz
Journal:  Nucleic Acids Res       Date:  1985-10-11       Impact factor: 16.971

8.  Cloning and expression of apolipoprotein B, the major protein of low and very low density lipoproteins.

Authors:  A J Lusis; R West; M Mehrabian; M A Reuben; R C LeBoeuf; J S Kaptein; D F Johnson; V N Schumaker; M P Yuhasz; M C Schotz
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

9.  Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.

Authors:  R W Milne; P K Weech; L Blanchette; J Davignon; P Alaupovic; Y L Marcel
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

10.  Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia.

Authors:  S G Young; S J Bertics; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.